HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cardiac transplant rejection — Clinical Guidelines

Overview

Cardiac transplant rejection occurs when the recipient's immune system attacks the transplanted heart, potentially leading to graft failure if not promptly diagnosed and treated. 2

Diagnosis

Histological Evaluation: Histopathological examination of endomyocardial biopsy samples is crucial for diagnosing rejection, grading it according to the International Society for Heart and Lung Transplantation (ISHLT) criteria. 2

Immunohistochemistry: Utilize monoclonal antibodies to identify specific leukocyte subsets involved in the rejection process, aiding in understanding the immune response dynamics. 2

Serum Biomarkers: Elevated serum creatine kinase levels may indicate myotoxicity, though not specific to rejection alone. 1

Electrodiagnostic Tests: Electromyography (EMG) can reveal features of myopathy and neuropathy, particularly relevant in patients on immunosuppressive agents like colchicine. 1

Management

Immunosuppressive Therapy: Adjust or switch calcineurin inhibitors (e.g., cyclosporine) and mTOR inhibitors based on rejection severity and patient-specific factors. 2

Antibody Therapy: Use intravenous immunoglobulins (IVIG) or specific anti-rejection monoclonal antibodies as adjunctive treatments in severe cases. 2

Colchicine Dose Adjustment: For patients requiring colchicine, especially those with renal insufficiency, reduce the dose to mitigate the risk of myoneuropathy. 1

Monitoring and Follow-Up: Regular endomyocardial biopsies and clinical monitoring are essential to assess rejection recurrence and adjust immunosuppressive regimens accordingly. 2

Special Populations

Renal Insufficiency: Patients with concurrent renal insufficiency are at higher risk for colchicine-induced myoneuropathy; dose adjustments are critical. 1

Key Recommendations

Monitor Renal Function and Adjust Colchicine Dose in cardiac transplant recipients with renal insufficiency to prevent myoneuropathy. (Evidence: Moderate 1)

Utilize Endomyocardial Biopsy for Diagnosis and Grading of cardiac transplant rejection according to ISHLT criteria. (Evidence: Strong 2)

Regularly Assess Immune Cell Subsets through immunohistochemistry to guide immunosuppressive therapy adjustments post-transplant. (Evidence: Moderate 2)

References

1 Rana SS, Giuliani MJ, Oddis CV, Lacomis D. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clinical neurology and neurosurgery 1997. link00092-9) 2 Forbes RD, Guttmann RD, Gomersall M, Hibberd J. Leukocyte subsets in first-set rat cardiac allograft rejection. A serial immunohistologic study using monoclonal antibodies. Transplantation 1983. link

Cardiac transplant rejection